Contineum Therapeutics, Inc.
CTNM
Rank in Stocks
#13786
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company,... Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Share Price
$10.30
Last synced: 2026-11-09
Market Cap
$364.14M
Change (1 day)
8.19%
Change (1 year)
-10.20%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Contineum Therapeutics, Inc. (CTNM)
Category
Healthcare
EPS for Contineum Therapeutics, Inc. (CTNM)
EPS as of September 2026 TTM: $-1.77
According to Contineum Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.77. At the end of 2025 the company had an EPS of $-2.17, a decrease compared to its 2024 EPS of $-1.63.
EPS history for Contineum Therapeutics, Inc. from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.77 | -18.43% |
| 2025 | $-2.17 | 33.13% |
| 2024 | $-1.63 | -1,353.85% |
| 2023 | $0.13 | -113.40% |
| 2022 | $-0.97 | -15.65% |
| 2021 | $-1.15 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -984.75% |
US
|
|
| $-7.07 | 299.44% |
US
|
|
| $-5.29 | 198.87% |
AU
|
|
| $12.88 | -827.69% |
BE
|
|
| $21.56 | -1,318.08% |
NL
|
Questions about Contineum Therapeutics, Inc.'s earnings per share (EPS)
What is Contineum Therapeutics, Inc.'s earnings per share (EPS)?
Contineum Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.77, as of Sep 2026.
What was Contineum Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Contineum Therapeutics, Inc.'s earnings per share (EPS) was $-2.17, compared with $-1.63 in 2024.
How has Contineum Therapeutics, Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, Contineum Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($0.13) and lowest in 2025 ($-2.17).
How does Contineum Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Contineum Therapeutics, Inc.'s earnings per share (EPS) ($-1.77) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.